Core Viewpoint - Tevogen Bio Holdings Inc. has executed a lease agreement to expand its corporate headquarters in Warren, New Jersey, significantly increasing its operational footprint and enhancing collaboration among its teams [2][3]. Group 1: Expansion and Operational Efficiency - The new headquarters will centralize various cross-functional teams, including executive leadership, regulatory affairs, corporate strategy, and research and development, which were previously located in Philadelphia [3]. - The expanded facility will also accommodate Tevogen.AI and the Generics & Biosimilars initiative, providing dedicated space for data scientists and engineers as the development of proprietary algorithms accelerates [3][4]. Group 2: Future Growth and Business Diversification - The newly leased space, previously occupied by CAPTRUST, will support potential new business units as Tevogen continues to grow and diversify its portfolio [4]. - Tevogen aims to finalize in-house manufacturing capabilities, which are projected to support cumulative revenues of $10–14 billion for Tevogen Oncology and $18–22 billion for Tevogen Specialty Care [5]. Group 3: Commitment to Healthcare - Tevogen remains dedicated to enhancing healthcare affordability and accessibility through drug development, AI-powered innovation, and domestic manufacturing of generics and biosimilars [5].

Core Insights - Tevogen Bio Holdings Inc. is advancing its artificial intelligence initiative, Tevogen.AI™, to enhance its immunotherapy development pipeline and reduce costs [1][2] Group 1: Tevogen.AI Initiative - Tevogen.AI aims to integrate machine learning and predictive modeling with ExacTcell™ technology to improve target identification and pre-clinical processes [2] - The initiative includes two proprietary technologies with patents pending, and the company plans to expand its AI applications beyond its current scope [3] Group 2: Strategic Partnerships - Tevogen has partnered with Microsoft for AI expertise and cloud infrastructure, and with Databricks for data engineering and analytics to enhance predictive accuracy [5] Group 3: Proprietary Technologies - PredicTcell™ utilizes AI to predict immunologically active peptide complexes, improving precision in immunotherapy treatments [6] - AdapTcell™ focuses on decoding interactions between human leukocyte antigens and T cells, enhancing understanding of immune responses [8][9] Group 4: Future Plans - Tevogen.AI plans to utilize its platforms for clinical trial patient identification, aiming for efficiency and cost reduction in drug development [10]

Core Insights - Tevogen Bio Holdings Inc. plans to expand the target population for its product TVGN 489 to include patients aged 65 and older, enhancing its market potential [1] - The top-line revenue forecast for the specialty care pipeline is projected at nearly $1 billion in its launch year, with a cumulative five-year estimate ranging between $18 billion and $22 billion [1] - The expansion aims to address significant unmet medical needs, particularly in light of the new COVID variant NB.1.8.1 [2] Company Developments - Tevogen's Chief Commercial Officer emphasized the importance of expanding clinical manufacturing capacity to meet the demands posed by the new COVID variant [2] - The expanded pipeline will include treatments for SARS-CoV-2 infection in various patient groups, including those with B cell hematologic cancer and patients aged 65 and older [5] Financial Projections - The updated forecast and risk-adjusted net present value (rNPV) will be provided to reflect the inclusion of the 65+ patient population [1] - The anticipated revenue growth reflects the company's strategic focus on specialty pharmaceuticals and addressing broader market needs [1]

Core Insights - Tevogen Bio Holdings Inc. is preparing to provide updates to stockholders ahead of its Annual Meeting scheduled for June 23, 2025, focusing on its innovative business model and strategic growth initiatives [1] Group 1: Portfolio Assets - The company will update investors on its portfolio assets, which include Tevogen Bio Oncology, Tevogen Bio Specialty Care, and Tevogen.AI, valued at over $10 billion as of October 2024 [2] Group 2: Corporate Highlights - Tevogen will detail two strategic initiatives: Tevogen.AI and Tevogen Generics & Biosimilars, alongside plans to expand its operational footprint with an upgraded headquarters [3] Group 3: Financial Market Dynamics - Management is monitoring stock dynamics, noting the impact of a limited tradable float and the growing institutional ownership, which reflects strong investor confidence and long-term holding patterns [4]

Financial Performance - Tevogen Bio reported a net loss of $10.4 million for the three months ended March 31, 2025, compared to a net loss of $11.3 million for the same period in 2024, primarily due to non-cash stock-based compensation expenses [136]. - The net loss for the three months ended March 31, 2025, was $10.4 million, compared to a net loss of $11.3 million for the same period in 2024 [156]. - Research and development expenses for the three months ended March 31, 2025, were $3.2 million, a decrease of 84.7% from $20.8 million for the same period in 2024 [157]. - General and administrative expenses for the three months ended March 31, 2025, were $7.2 million, down 17.7% from $8.7 million in the same period in 2024 [158]. - Cash used in operating activities for the three months ended March 31, 2025, was $3.3 million, compared to $2.2 million for the same period in 2024 [165][166]. Cash and Funding - As of March 31, 2025, Tevogen Bio had an accumulated deficit of $123.8 million and cash reserves of $2.0 million [136]. - As of March 31, 2025, the company had $2.0 million in cash, an increase from $1.3 million as of December 31, 2024 [163]. - The company raised aggregate gross proceeds of $24.0 million from the sale of convertible promissory notes since January 2021 [163]. - The company has drawn $3.0 million from a Loan Agreement with a remaining $27.0 million available for future financing [163]. - The company expects to utilize $8.0 million in grant funding from KRHP for ongoing operational expenses through March 31, 2026 [176]. - The company is exploring various funding strategies, including private placements and partnerships, to support operations [177]. Clinical Development - The first clinical product, TVGN 489, has completed a Phase 1 proof-of-concept trial with no dose-limiting toxicities observed, and secondary endpoints showed a rapid reduction in viral load [126]. - The company aims to commercialize TVGN 489 and other product candidates, expecting to incur expenses related to expanding research and development capabilities and building manufacturing infrastructure [141]. - The company plans to conduct clinical trials for TVGN 489 and other product candidates, which will require considerable financial resources [172]. - The company anticipates increased expenses related to commercialization if marketing approval for TVGN 489 is obtained [174]. Patent and Technology - Tevogen Bio's patent portfolio includes three issued U.S. patents related to TVGN 489, all expiring on December 9, 2040, and nine pending U.S. patent applications [130][131]. - Tevogen Bio's ExacTcell technology is designed to develop off-the-shelf T cell therapies with applications in infectious diseases and cancers [124]. Future Expectations - The company has not generated any revenue to date and does not expect to do so until marketing approval is obtained for its product candidates [141]. - The company expects general and administrative expenses to increase in the future to support ongoing research and development and potential commercialization efforts [149]. - The company expects to incur costs associated with operating as a public company, necessitating additional funding [174]. Obligations and Agreements - Total contractual obligations as of March 31, 2025, amount to $4,846,712, with $1,846,712 due within one year [179]. - The company has committed to a securities purchase agreement with the Patel Family for $6.0 million in Series C Preferred Stock [170]. - The company has not yet received $3.0 million of the $6.0 million purchase price for Series A-1 Preferred Stock [170]. - The company has entered into a Loan Agreement allowing for monthly draws of up to $1.0 million over 27 months, with a maximum loan amount of $36.0 million [171]. - The company has drawn an aggregate of $3.0 million under the Loan Agreement as of March 31, 2025, with an additional $0.5 million drawn in April 2025 [171].

Group 1 - Tevogen Bio Holdings Inc. has received inquiries from shareholders about transferring shares to the Direct Registration System (DRS) following a recent press release [1] - The company will provide step-by-step guidance next week for shareholders to register their shares directly with the transfer agent, Continental Stock Transfer & Trust [2] - Several of Tevogen's largest shareholders have chosen to hold their shares via DRS, indicating their confidence in this method of ownership [2]

Core Viewpoint - Tevogen Bio Holdings Inc. has signed a letter of intent with CD8 Technology Services LLC to establish a facility that will support its cell therapy manufacturing, emphasizing the importance of in-house manufacturing for operational efficiency and highlighting significant insider ownership at 74% [1]. Company Summary - Tevogen's CEO, Ryan Saadi, stated that in-house manufacturing is critical for operational efficiency [1]. - The company has a notable insider ownership of 74%, indicating a strong commitment to business discipline [1]. Industry Context - The agreement with CD8 is expected to enhance Tevogen's research and manufacturing capabilities, particularly in building GMP (Good Manufacturing Practice) capabilities at scale [2]. - The company aims to develop product candidates for treating infectious diseases and cancer, which aligns with trends in the healthcare and biopharmaceutical industries [2].

Core Viewpoint - Tevogen Bio Holdings Inc. informs shareholders about the differences between holding shares in Direct Registration System (DRS) accounts versus brokerage accounts, highlighting the benefits and drawbacks of each option [1]. Group 1: DRS Accounts - DRS accounts allow shares to be registered directly in the shareholder's name, providing direct control over the shares [2]. - Holding shares in DRS accounts may result in reduced transaction and account maintenance costs for shareholders [2]. Group 2: Brokerage Accounts - Brokerage accounts may offer greater access to investment tools and facilitate quicker selling of shares compared to DRS accounts [2]. - Investors may incur costs associated with transferring shares in and out of brokerage accounts [2]. Group 3: Additional Information - For further details regarding the differences between DRS and brokerage accounts, shareholders are encouraged to contact the Company's transfer agent, Continental Stock Transfer & Trust [3].

Reflects business philosophy of commercial success through patient accessibilityRecently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company’s dedicated R&D and manufacturing facility; no impact on shareholder equity WARREN, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5- ...

Core Viewpoint - Tevogen Bio Holdings Inc. will hold its 2025 annual meeting of stockholders via live webcast on June 23, 2025, where stockholders will vote on the re-election of two directors and the ratification of the independent accounting firm [1] Group 1 - Stockholders of record as of April 30, 2025, are encouraged to participate in the voting process, with proxy materials to be distributed in accordance with SEC regulations [2] - The Company plans to disclose the voting results on a Form 8-K after the Annual Meeting [3] - A proxy statement will be filed with the SEC, which stockholders are urged to read carefully as it will contain important information about the Company and the Annual Meeting [4] Group 2 - Stockholders can obtain free copies of the proxy statement and other SEC filings from the SEC's website or the Company's Investor Relations page [5] - The Company and its directors and executive officers may be considered participants in the proxy solicitation, with relevant information to be included in the proxy statement [6]